Mirum Pharmaceuticals (MIRM) executive compensation, 2026 proxy

Christopher Peetz, Chief Executive Officer, was paid $10.4M in 2025, up 58% from $6.6M the year before. The CEO-to-median-employee pay ratio was 24:1, on median employee pay of $434,769.

Filed
April 23, 2026
Annual meeting
June 15, 2026
Pay year
2025
Named executives
4
CEO total pay
$10.4M+58% vs prior year
CEO to median employee
24:1median $434,769
CEO pay in equity
83%$8.6M in awards
Prior say-on-pay support
96%of votes cast
CEO Total Compensation
$10,441,224For fiscal year 2025
CEO Salary
$755,000Base salary for 2025
CEO Non-Equity Incentive
$1,057,000Performance-based bonus earned
CEO Pay Ratio
24:1Compared to median employee

How Peetz was paid

$10.4M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary7%Stock awards35%Option awards47%Non-equity incentive10%All other compensation0%

Named executive officers

ExecutiveTotal
Christopher PeetzChief Executive Officer$10,441,224
Eric BjerkholtChief Financial Officer$3,246,216
Peter RadovichPresident and Chief Operating Officer$3,964,270
Joanne Quan, M.D.Chief Medical Officer$3,246,216

What changed and why

  • $10.4MChristopher Peetz received total compensation of $10,441,224 for fiscal year 2025, representing an increase over his prior year total.
  • Stock and option awards formed the majority of the CEO compensation package for the year.
  • $1.1MNon-equity incentive compensation of $1,057,000 was awarded to the CEO based on 2025 performance.
  • 96%The advisory say-on-pay vote at the 2025 annual meeting received approximately 96% support from stockholders.
  • The CEO to median employee pay ratio for 2025 was calculated to be 24 to 1.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.